Drug Profile
Adalimumab biosimilar - Bionovis/The Instituto Vital Brazil
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Bionovis; The Instituto Vital Brazil
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Discontinued Ulcerative colitis
Most Recent Events
- 09 Oct 2023 Adalimumab biosimilar is still in clinical development in Crohn's-disease in Brazil (SC, Injection) (Bionovis pipeline, October 2023)
- 09 Oct 2023 Adalimumab biosimilar is still in clinical development in Psoriatic-arthritis in Brazil (SC, Injection) (Bionovis pipeline, October 2023)
- 09 Oct 2023 Adalimumab biosimilar is still in clinical development in Rheumatoid-arthritis in Brazil (SC, Injection) (Bionovis pipeline, October 2023)